These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 31470905)

  • 1. The "rights" of precision drug development for Alzheimer's disease.
    Cummings J; Feldman HH; Scheltens P
    Alzheimers Res Ther; 2019 Aug; 11(1):76. PubMed ID: 31470905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Biomarkers in Alzheimer's Disease Drug Development.
    Cummings J
    Adv Exp Med Biol; 2019; 1118():29-61. PubMed ID: 30747416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.
    Cummings J; Ritter A; Zhong K
    J Alzheimers Dis; 2018; 64(s1):S3-S22. PubMed ID: 29562511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease
.
    Hampel H; Vergallo A; Afshar M; Akman-Anderson L; Arenas J; Benda N; Batrla R; Broich K; Caraci F; Cuello AC; Emanuele E; Haberkamp M; Kiddle SJ; Lucía A; Mapstone M; Verdooner SR; Woodcock J; Lista S
    Dialogues Clin Neurosci; 2019; 21(2):177-191. PubMed ID: 31636492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision pharmacology for Alzheimer's disease.
    Hampel H; Vergallo A; Aguilar LF; Benda N; Broich K; Cuello AC; Cummings J; Dubois B; Federoff HJ; Fiandaca M; Genthon R; Haberkamp M; Karran E; Mapstone M; Perry G; Schneider LS; Welikovitch LA; Woodcock J; Baldacci F; Lista S;
    Pharmacol Res; 2018 Apr; 130():331-365. PubMed ID: 29458203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapies for sleep disturbances in Alzheimer's disease.
    McCleery J; Cohen DA; Sharpley AL
    Cochrane Database Syst Rev; 2014 Mar; (3):CD009178. PubMed ID: 24659320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot.
    Hampel H; Lista S; Khachaturian ZS
    Alzheimers Dement; 2012 Jul; 8(4):312-36. PubMed ID: 22748938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Alzheimer's disease drug development landscape.
    van Bokhoven P; de Wilde A; Vermunt L; Leferink PS; Heetveld S; Cummings J; Scheltens P; Vijverberg EGB
    Alzheimers Res Ther; 2021 Nov; 13(1):186. PubMed ID: 34763720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision medicine and drug development in Alzheimer's disease: the importance of sexual dimorphism and patient stratification.
    Hampel H; Vergallo A; Giorgi FS; Kim SH; Depypere H; Graziani M; Saidi A; Nisticò R; Lista S;
    Front Neuroendocrinol; 2018 Jul; 50():31-51. PubMed ID: 29902481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating ADNI results into Alzheimer's disease drug development programs.
    Cummings JL
    Neurobiol Aging; 2010 Aug; 31(8):1481-92. PubMed ID: 20447734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Cedarbaum J; Green RC; Harvey D; Jack CR; Jagust W; Luthman J; Morris JC; Petersen RC; Saykin AJ; Shaw L; Shen L; Schwarz A; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2015 Jun; 11(6):e1-120. PubMed ID: 26073027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nimodipine for primary degenerative, mixed and vascular dementia.
    López-Arrieta JM; Birks J
    Cochrane Database Syst Rev; 2002; (3):CD000147. PubMed ID: 12137606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Critical Role of Biomarkers for Drug Development Targeting the Biology of Aging.
    Owen M; Bose N; Nisenbaum L; Partrick KA; Fillit HM
    J Prev Alzheimers Dis; 2023; 10(4):729-742. PubMed ID: 37874093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers for preclinical Alzheimer's disease.
    Tan CC; Yu JT; Tan L
    J Alzheimers Dis; 2014; 42(4):1051-69. PubMed ID: 25024325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.
    Ossenkoppele R; van der Kant R; Hansson O
    Lancet Neurol; 2022 Aug; 21(8):726-734. PubMed ID: 35643092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?
    Messner DA; Rabins P; Downing AC; Irizarry M; Foster NL; Al Naber J; Dabbous O; Fillit H; Gabler S; Krakauer R; Lotz D; Payzant E; Schneider L; Tyrone J; Van Amerongen D; Wuest D
    J Prev Alzheimers Dis; 2019; 6(1):20-26. PubMed ID: 30569082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.